Cyfra 21-1 Test
The Cyfra 21-1 test measures the levels of a fragment of cytokeratin 19 in the blood. Cyfra 21-1 is a tumor marker that is often elevated in individuals with non-small cell lung cancer (NSCLC). It is commonly used to monitor treatment response in patients with lung cancer, particularly NSCLC, and to detect possible recurrence. It can also be elevated in some other cancers and benign lung conditions.
Cyfra 21-1 Test
- Price: £ 105
- Code: MLCYF
Tests Included
The test evaluates the concentration of Cyfra 21-1, a fragment of cytokeratin 19 that is released into the bloodstream when cells break down. Elevated levels can indicate non-small cell lung cancer (NSCLC) and other types of cancer, making it a valuable tool for monitoring treatment or checking for cancer recurrence.
FAQs
This test is recommended if you are undergoing treatment for non-small cell lung cancer (NSCLC). It can help track the effectiveness of your therapy and detect recurrence. The test may also be used to monitor other cancers, especially if your healthcare provider has noted elevated Cyfra 21-1 levels previously.
A blood sample is taken from a vein in your arm and analyzed in the laboratory to determine the Cyfra 21-1 levels.
Results are typically available within 1–2 working days. You will be notified by email or text once your results are ready.
No special preparation is required for the Cyfra 21-1 test. However, you should inform your healthcare provider if you are undergoing cancer treatment, as this can influence the test results.
Book Cyfra 21-1 Test Today!
Stay on top of your health with the Cyfra 21-1 test. For £105, gain essential insights into your cancer treatment progress or evaluate potential concerns.